| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Recombinant full-length human CREB5 protein was used as the immunogen for the CREB5 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
The ATF/CREB family consists of a series of transcription factors that function by binding to the cAMP responsive element (CRE) palindromic octanucleotide, TGACCTCA. The best characterized members of this gene family include CREB-1, CREB-2 (also designated ATF-4), CRE-BPa, LZIP (also designated CREB-3 and Luman), CREM-2, ATF-1, ATF-2, ATF-3, ATF-5, ATF-6 and ATF-7. These transcription factors share terminal leucine zipper dimerization and basic DNA binding domains and are highly variable in their N-termini. Although each of the ATF/ CREB proteins bind CREs in their homodimeric form, they can also bind as heterodimers, both within the ATF/CREB family and with members of the AP-1 transcription factor family. Protein kinase A- mediated CREB phosphorylation induces association with a nuclear protein designated CBP (CREB-binding protein), which may represent a CREB coactivator. CRE-BPa is a nuclear protein that binds DNA as a homodimer but can also form a heterodimer with ATF-2 or Jun.
This anti-CREB5 antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone PCRP-CREB5-1G8, Mouse IgG2b, kappa, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.
Key elements and design rationale
- Target: CREB5
- Format: Purified
- Localization: Nucleus
- Species reactivity: Human
- Applications (listed): FACS, IF, WB
- Conjugate: Unconjugated
- Clone and antibody class: Monoclonal (mouse origin), clone PCRP-CREB5-1G8, Mouse IgG2b, kappa
Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.
Biological background
CREB5 is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.
Research relevance and current trends
- Profiling CREB5 expression across model systems, perturbations, and time points to support mechanistic hypotheses.
- Combining antibody-based detection with multi-omics or imaging readouts to link CREB5 signal with phenotype.
- Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.
Common research applications
- FACS
- IF
- WB
Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.
Notes for experimental interpretation
- Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
- Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
- Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.